Skip to main content
Top
Published in: Digestive Diseases and Sciences 5/2009

01-05-2009 | ORIGINAL ARTICLE

Crohn’s Disease in India: A Multicenter Study from a Country Where Tuberculosis Is Endemic

Authors: Kshaunish Das, Uday C. Ghoshal, Gopal K. Dhali, Jaya Benjamin, Vineet Ahuja, Govind K. Makharia

Published in: Digestive Diseases and Sciences | Issue 5/2009

Login to get access

Abstract

Although Crohn’s disease is thought to be rare and intestinal tuberculosis common in India, Crohn’s disease is being reported more often. However, there is a lack of systematic study on Crohn’s disease from India. In this analysis of data from three inflammatory bowel disease clinics (two in northern India and one in eastern India), criteria for Crohn’s disease were applied retrospectively: (1) World Health Organization (WHO) criteria; or (2) compatible histology (European Crohn’s and Colitis Organization) or failure of response to 4–8 weeks of anti-tuberculosis therapy (Asia-Pacific guidelines); or (3) compatible macroscopic, radiologic, colonoscopic features (European Crohn’s and Colitis Organization). Others were classified as probable Crohn’s disease. The Montreal classification was used for disease phenotype. Age at onset and duration of symptoms (182 patients, 117 male) were 34.5 (±13.6; 7–73) years and 3.0 (±5.8; 0.1–36) years, respectively. Diarrhea (68%), abdominal pain (62%), and weight loss (57%) were common. The common intestinal complications were occult (27%) and overt (40%) gastrointestinal bleeding and obstruction (28%). There were 141 (78%) and 41 (22%) with definite and probable Crohn’s disease respectively. Of 147 (81%) available histopathology specimens (endoscopic biopsy in 110; 75%), 31 (21%) had granuloma. Seventy-one out of 166 (43%) had received anti-tuberculosis therapy in the past. Results from the Montreal classification were as follows: age at onset, A1:A2:A3 6%:64%:30%; location of disease, L1:L2:L3:L4 32%:41%:23%:4%, and disease behavior, B1:B2:B3 51%:24%:25%. Twenty-six (15%) and 31 (17%) patients had upper gastrointestinal and perianal modifiers. The drugs used were: aminosalicylates (128, 70%), steroids (76, 42%), azathioprine (53, 29%), methotrexate (4, 2%), and salazopyrine (14, 8%). Sixty-six (36%) patients underwent surgical treatment. We concluded that the phenotype of Crohn’s disease in India is very similar to that described in other regions of Asia and the West, except for a delay in diagnosis and a more complicated disease at diagnosis.
Literature
2.
go back to reference Ouyang Q, Tandon R, Goh KL, Ooi CJ, Ogata H, Fiocchi C. The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol. 2005;21:408–413.PubMed Ouyang Q, Tandon R, Goh KL, Ooi CJ, Ogata H, Fiocchi C. The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol. 2005;21:408–413.PubMed
5.
7.
go back to reference Jayanthi V, Probert CSJ, Pinder D, Wicks ACB, Mayberry JF. Epidemiology of Crohn’s disease in Indian migrants and the indigenous population in Leicestershire. QJM. 1992;82:125–138.PubMed Jayanthi V, Probert CSJ, Pinder D, Wicks ACB, Mayberry JF. Epidemiology of Crohn’s disease in Indian migrants and the indigenous population in Leicestershire. QJM. 1992;82:125–138.PubMed
8.
go back to reference Hilmi I, Tan YM, Goh KL. Crohn’s disease in adults: observations in a multiracial Asian population. World J Gastroenterol. 2006;12:1435–1438.PubMed Hilmi I, Tan YM, Goh KL. Crohn’s disease in adults: observations in a multiracial Asian population. World J Gastroenterol. 2006;12:1435–1438.PubMed
9.
go back to reference Gupta RS, Chatterjee AK, Roy R, Ghosh BN. A review of the results of treatment of 44 cases of Crohn’s disease. Indian J Surg. 1962;24:787–805. Gupta RS, Chatterjee AK, Roy R, Ghosh BN. A review of the results of treatment of 44 cases of Crohn’s disease. Indian J Surg. 1962;24:787–805.
11.
go back to reference Venugopalan S, Radhakrishnan S, Rajachandrasekharan R. Crohn’s disease (a study of 21 cases). Indian J Surg. 1980;42:388–396. Venugopalan S, Radhakrishnan S, Rajachandrasekharan R. Crohn’s disease (a study of 21 cases). Indian J Surg. 1980;42:388–396.
12.
go back to reference Antia FP. Crohn’s conundrum in Indians. Indian J Gastroenterol. 1986;5:79–80.PubMed Antia FP. Crohn’s conundrum in Indians. Indian J Gastroenterol. 1986;5:79–80.PubMed
14.
go back to reference Pai CG, Khandige GK. Is Crohn’s disease rare in India? Indian J Gastroenterol. 2000;19:17–20.PubMed Pai CG, Khandige GK. Is Crohn’s disease rare in India? Indian J Gastroenterol. 2000;19:17–20.PubMed
15.
go back to reference Benjamin J, Makharia GK, Ahuja V, Kalaivani M, Joshi YK. Intestinal permeability and its association with the patient and disease characteristics in Crohn’s disease. World J Gastroenterol. 2008;14:1399–1405. doi:10.3748/wjg.14.1399.PubMedCrossRef Benjamin J, Makharia GK, Ahuja V, Kalaivani M, Joshi YK. Intestinal permeability and its association with the patient and disease characteristics in Crohn’s disease. World J Gastroenterol. 2008;14:1399–1405. doi:10.​3748/​wjg.​14.​1399.PubMedCrossRef
16.
17.
go back to reference Ray G, Banerjee PK, Ghoshal UC, et al. Etiology and management of obscure gastrointestinal bleed—an appraisal from eastern India. Indian J Gastroenterol. 2001;20:90–93.PubMed Ray G, Banerjee PK, Ghoshal UC, et al. Etiology and management of obscure gastrointestinal bleed—an appraisal from eastern India. Indian J Gastroenterol. 2001;20:90–93.PubMed
21.
go back to reference Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease in the last five decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007;13:481–489. doi:10.1002/ibd.20036.PubMedCrossRef Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease in the last five decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007;13:481–489. doi:10.​1002/​ibd.​20036.PubMedCrossRef
22.
23.
go back to reference Lapidus A, Bernell O, Hellers G, Persson PG, Löfberg R. Incidence of Crohn’s disease in Stockholm County 1955–1989. Gut. 1997;41:480–486.PubMed Lapidus A, Bernell O, Hellers G, Persson PG, Löfberg R. Incidence of Crohn’s disease in Stockholm County 1955–1989. Gut. 1997;41:480–486.PubMed
24.
go back to reference Lapidus A. Crohn’s disease in Stockholm County during 1990–2001: An epidemiological update. World J Gastroenterol. 2006;12:75–81.PubMed Lapidus A. Crohn’s disease in Stockholm County during 1990–2001: An epidemiological update. World J Gastroenterol. 2006;12:75–81.PubMed
25.
go back to reference Tsianos EV, Masalas CN, Merkouropoulos M, Dalekos GN, Logan RF. Incidence of inflammatory bowel disease in northwest Greece: rarity of Crohn’s disease in an area where ulcerative colitis is common. Gut. 1994;35:369–372. doi:10.1136/gut.35.3.369.PubMedCrossRef Tsianos EV, Masalas CN, Merkouropoulos M, Dalekos GN, Logan RF. Incidence of inflammatory bowel disease in northwest Greece: rarity of Crohn’s disease in an area where ulcerative colitis is common. Gut. 1994;35:369–372. doi:10.​1136/​gut.​35.​3.​369.PubMedCrossRef
26.
go back to reference Mekjian HS, Switz DM, Melnyk CS, Rankin GB, Brooks RK. Clinical features and natural history of Crohn’s disease. Gastroenterology. 1979;77:898–906. Mekjian HS, Switz DM, Melnyk CS, Rankin GB, Brooks RK. Clinical features and natural history of Crohn’s disease. Gastroenterology. 1979;77:898–906.
28.
go back to reference Munkholm P, Binder V. Clinical features and natural history of Crohn’s disease. In: Sartor RB, Sandborn WJ, eds. Kirsner’s Inflammatory Bowel Diseases. 6th ed. Edinburgh: Saunders; 2004:289. Munkholm P, Binder V. Clinical features and natural history of Crohn’s disease. In: Sartor RB, Sandborn WJ, eds. Kirsner’s Inflammatory Bowel Diseases. 6th ed. Edinburgh: Saunders; 2004:289.
29.
go back to reference Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi F, Belaiche J. Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49:777–782. doi:10.1136/gut.49.6.777.PubMedCrossRef Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi F, Belaiche J. Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49:777–782. doi:10.​1136/​gut.​49.​6.​777.PubMedCrossRef
30.
go back to reference Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998;42:387–391.PubMed Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998;42:387–391.PubMed
31.
go back to reference Chadha VK. Tuberculosis epidemiology in India: a review. Int J Tuberc Lung Dis. 2005;9:1072–1082.PubMed Chadha VK. Tuberculosis epidemiology in India: a review. Int J Tuberc Lung Dis. 2005;9:1072–1082.PubMed
32.
go back to reference Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut. 1996;39:690–697. doi:10.1136/gut.39.5.690.PubMedCrossRef Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut. 1996;39:690–697. doi:10.​1136/​gut.​39.​5.​690.PubMedCrossRef
34.
go back to reference Selby W, Pavli P, Crotty B, et al., Antibiotics in Crohn’s Disease Study Group. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine in Crohn’s disease. Gastroenterology. 2007;132:2313–2319. doi:10.1053/j.gastro.2007.03.031. Selby W, Pavli P, Crotty B, et al., Antibiotics in Crohn’s Disease Study Group. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine in Crohn’s disease. Gastroenterology. 2007;132:2313–2319. doi:10.​1053/​j.​gastro.​2007.​03.​031.
35.
go back to reference Balasubramanian R, Nagarajan M, Balambal R, et al. Randomised controlled clinical trial of short course chemotherapy in abdominal tuberculosis: a 5-year report. Int J Tuberc Lung Dis. 1997;1:44–51.PubMed Balasubramanian R, Nagarajan M, Balambal R, et al. Randomised controlled clinical trial of short course chemotherapy in abdominal tuberculosis: a 5-year report. Int J Tuberc Lung Dis. 1997;1:44–51.PubMed
36.
go back to reference Ghoshal UC, Ghoshal U, Singh H, Tiwari S. Anti-Saccharomyces cerevisiae antibody is not useful to differentiate between Crohn’s disease and intestinal tuberculosis in India. J Postgrad Med. 2007;53:166–170.PubMedCrossRef Ghoshal UC, Ghoshal U, Singh H, Tiwari S. Anti-Saccharomyces cerevisiae antibody is not useful to differentiate between Crohn’s disease and intestinal tuberculosis in India. J Postgrad Med. 2007;53:166–170.PubMedCrossRef
37.
go back to reference Epstein D, Watermeyer G, Kirsch R. Review article: the diagnosis and management of Crohn’s disease in populations with high-risk rates for tuberculosis. Aliment Pharmacol Ther. 2007;25:1373–1388.PubMedCrossRef Epstein D, Watermeyer G, Kirsch R. Review article: the diagnosis and management of Crohn’s disease in populations with high-risk rates for tuberculosis. Aliment Pharmacol Ther. 2007;25:1373–1388.PubMedCrossRef
38.
go back to reference Heresbach D, Alexandre JL, Branger B, et al., ABERMAD. Frequency and significance of granulomas in a cohort of incident cases of Crohn’s disease. Gut. 2005;54:215–222. doi:10.1136/gut.2004.041715. Heresbach D, Alexandre JL, Branger B, et al., ABERMAD. Frequency and significance of granulomas in a cohort of incident cases of Crohn’s disease. Gut. 2005;54:215–222. doi:10.​1136/​gut.​2004.​041715.
40.
go back to reference Solberg IC, Vatn MH, Høie O, et al., Ibsen Study Group. Clinical course in Crohn’s disease: results of a Norwegian population-based 10-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430–1438. doi:10.1016/j.cgh.2007.09.002. Solberg IC, Vatn MH, Høie O, et al., Ibsen Study Group. Clinical course in Crohn’s disease: results of a Norwegian population-based 10-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430–1438. doi:10.​1016/​j.​cgh.​2007.​09.​002.
Metadata
Title
Crohn’s Disease in India: A Multicenter Study from a Country Where Tuberculosis Is Endemic
Authors
Kshaunish Das
Uday C. Ghoshal
Gopal K. Dhali
Jaya Benjamin
Vineet Ahuja
Govind K. Makharia
Publication date
01-05-2009
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 5/2009
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-008-0469-6

Other articles of this Issue 5/2009

Digestive Diseases and Sciences 5/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.